@article{57b398ac19a243948cac55f1a5cca398,
title = "Does financial hardship associate with abnormal quantitative myocardial perfusion and major adverse cardiovascular event?",
abstract = "Background: Data on impact of financial hardship on coronary artery disease (CAD) remain incomplete. Methods: Consecutive subjects referred for clinical rest/stress cardiac positron emission tomography (PET) were enrolled. Financial hardship is defined as patients{\textquoteright} inability to pay for their out-of-pocket expense for cardiac PET. Abnormal cardiac PET is defined as at least moderate relative perfusion defects at stress involving > 10% of the left ventricle or global coronary flow reserve ≤ 2.0. Patients were followed for major adverse cardiovascular event (MACE) comprised of all-cause mortality, non-fatal myocardial infarction, and late coronary revascularization. Results: We analyzed a total of 4173 patients with mean age 65.6 ± 11.3 years, 72.2% men, and 93.6% reported as having medical insurance. Of these, 504 (12.1%) patients had financial hardship. On multivariable analysis, financial hardship associated with abnormal cardiac PET (odds ratio 1.377, p = 0.004) and MACE (hazard ratio 1.432, p = 0.010) and its association with MACE was mostly through direct effect with small proportion mediated by abnormal cardiac PET or known CAD. Conclusion: Among patients referred for cardiac rest/stress PET, financial hardship independently associates with myocardial perfusion abnormalities and MACE; however, its effect on MACE is largely not mediated by abnormal myocardial perfusion or known CAD suggesting distinct impact of financial hardship beyond traditional risk factors and CAD that deserves attention and intervention to effectively reduced adverse outcomes. Having medical insurance does not consistently protect from financial hardship and a more preventive-oriented restructuring may provide better outcomes at lower cost.",
keywords = "CAD, Diagnostic and prognosticapplication, Diseases/processes, Modalities, Myocardial blood flow, Outcomes, PET, Tests",
author = "Danai Kitkungvan and Johnson, {Nils P.} and Linh Bui and Patel, {Monica B.} and Roby, {Amanda E.} and Mary Haynie and Richard Kirkeeide and Susan Hood and Gould, {K. Lance}",
note = "Funding Information: Research supported by internal funds of the Weatherhead PET Center No authors have a relationship with industry related to this manuscript. NPJ received internal funding from Weatherhead PET Center for Preventing and Reversing Atherosclerosis and research support from St. Jude Medical (for NCT02184117) and Volcano/Philips Corporation (for NCT02328820). KLG received internal funding from the Weatherhead PET Center and is the applicant for 510(k) FDA cleared HeartSee K171303 PET software. To avoid any conflict of interest, KLG assigned any royalties arising from PET software to UT for research or student scholarships. Publisher Copyright: {\textcopyright} 2023, The Author(s) under exclusive licence to American Society of Nuclear Cardiology.",
year = "2023",
doi = "10.1007/s12350-022-03184-1",
language = "English (US)",
journal = "Journal of Nuclear Cardiology",
issn = "1071-3581",
publisher = "Springer New York",
}